Updates are available Correction dated 2019-04-11

Article History

Received: 25 October 2018

Revised: 15 January 2019

Accepted: 21 January 2019

First Online: 21 February 2019

Change Date: 11 April 2019

Change Type: Correction

Change Details: The article listed above was initially published with incorrect copyright information. Upon publication of this Correction, the copyright of this article changed to “The Author(s)”. The original article has been corrected.

Compliance with ethical standards

:

: RA: grant/research support: Bristol-Myers Squibb; speakers bureau: Bristol-Myers Squibb. XM: grant/research support: Biogen, Pfizer, UCB; speakers bureau: Bristol-Myers Squibb, LFB, GSK, Pfizer, UCB. H-ML: consulting fees: AbbVie, Bristol-Myers Squibb, Roche-Chugai, UCB, MSD, GSK, Sobi, Medac, Novartis, Janssen-Cilag, AstraZeneca, Pfizer, Actelion. HN: consulting fees: AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, UCB. MG: none declared. FN: grant/research support: Pfizer, MSD, AbbVie, Bristol-Myers Squibb, Roche; speakers bureau: Pfizer, MSD, Roche, UCB, AbbVie, Bristol-Myers Squibb; consultant: Pfizer, MSD, Roche, UCB, AbbVie, Bristol-Myers Squibb, Janssen, Lilly. MC: employee: Bristol-Myers Squibb. JH: consultant: Bristol-Myers Squibb. CP: consultant: Bristol-Myers Squibb. CR: shareholder and employee: Bristol-Myers Squibb. MLB: shareholder and employee: Bristol-Myers Squibb (at time of study).

: The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization Good Clinical Practice Guidelines, and the Good Epidemiological Practice Guidelines. All enrolled patients provided informed consent in accordance with local laws.